BunyaVax

Overview
Animal Therapeutics?
Product stageSegments
Early
?
Next-generation vaccines and drugs
?

BunyaVax is a spin-off company from Wageningen University & Research (WUR) in the Netherlands. It manages the LARISSA consortium, which is developing a novel live-attenuated Rift Valley fever vaccine called hRVFV-4s. The vaccine virus was initially constructed by genetic engineering in 2014 and found to be highly safe and efficacious in ruminants.

BunyaVax's hRVFV-4s vaccine candidate reached a significant milestone in August 2022 when the first healthy volunteer was dosed in a Phase I clinical trial in Belgium. This dose escalation study aims to assess the safety, tolerability, and immunogenicity of the vaccine candidate in healthy adult volunteers. Following a single dose administration, hRVFV-4s is expected to generate a long-lasting immune response against Rift Valley fever, a severe and potentially deadly disease predominantly transmitted by mosquitoes.

In October 2023, the Coalition for Epidemic Preparedness Innovations (CEPI) announced an expanded partnership with Wageningen Bioveterinary Research (WBVR), BunyaVax's parent organization, to advance hRVFV-4s through a multi-site Phase I/IIa clinical trial. These trials are scheduled to begin in 2025 in Kenya and Uganda, where Rift Valley fever poses a significant threat to rural communities. CEPI's investment of up to USD 25.9 million, supported by the European Union's Horizon Europe programme, will fund these trials, an extension of the ongoing Phase I study, manufacturing of clinical trial materials, epidemiological research, and regulatory efforts toward licensure.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
Houtribweg 39 Lelystad NLD
Founded year:
2017
Employees:
1-10
IPO status:
Private
Total funding:
USD 83.3 k
Last Funding:
USD 83.3 k (Grant; Jun 2018)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...

EDGE Insights

Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.